- Home
- ODYS vs CRBU Comparison
ODYS vs CRBU Comparison
Compare ODYS & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODYS
- CRBU
- Stock Information
- Founded
- ODYS N/A
- CRBU 2011
- Country
- ODYS Israel
- CRBU United States
- Employees
- ODYS N/A
- CRBU N/A
- Industry
- ODYS
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- ODYS
- CRBU Health Care
- Exchange
- ODYS NYSE
- CRBU Nasdaq
- Market Cap
- ODYS 107.4M
- CRBU 93.0M
- IPO Year
- ODYS N/A
- CRBU 2021
- Fundamental
- Price
- ODYS $5.31
- CRBU $0.79
- Analyst Decision
- ODYS Strong Buy
- CRBU Strong Buy
- Analyst Count
- ODYS 1
- CRBU 5
- Target Price
- ODYS $10.00
- CRBU $10.60
- AVG Volume (30 Days)
- ODYS 38.0K
- CRBU 1.0M
- Earning Date
- ODYS 03-28-2025
- CRBU 05-16-2025
- Dividend Yield
- ODYS N/A
- CRBU N/A
- EPS Growth
- ODYS N/A
- CRBU N/A
- EPS
- ODYS N/A
- CRBU N/A
- Revenue
- ODYS $3,964,000.00
- CRBU $9,994,000.00
- Revenue This Year
- ODYS N/A
- CRBU N/A
- Revenue Next Year
- ODYS N/A
- CRBU $163.34
- P/E Ratio
- ODYS N/A
- CRBU N/A
- Revenue Growth
- ODYS 30.70
- CRBU N/A
- 52 Week Low
- ODYS $5.01
- CRBU $0.66
- 52 Week High
- ODYS $10.80
- CRBU $4.21
- Technical
- Relative Strength Index (RSI)
- ODYS N/A
- CRBU 44.91
- Support Level
- ODYS N/A
- CRBU $0.77
- Resistance Level
- ODYS N/A
- CRBU $0.91
- Average True Range (ATR)
- ODYS 0.00
- CRBU 0.08
- MACD
- ODYS 0.00
- CRBU 0.01
- Stochastic Oscillator
- ODYS 0.00
- CRBU 32.97
About ODYS ODYSIGHT AI INC
Odysight ai Inc is engaged in the development, production, and marketing of innovative Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for critical systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.